Company: TVRD
Filing Date: 2025-01-17
Form Type: 425
Source: 0001104659-25-004519
Chunk: 5

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-17
Form: 425
Chunk 5
---
 Company’s directors and executive officers
and their respective affiliates have acquired or disposed of security holdings since the applicable “as of” date
disclosed in the 2024 Cara Proxy Statement, such transactions have been or will be reflected on Statements of Change in Beneficial
Ownership on Form 4 filed with the SEC. Additional information regarding the persons who may be deemed participants in the proxy
solicitation, including the information about the directors and executive officers of Tvardi, and a description of their direct and
indirect interests, by security holdings or otherwise, are also included in a registration statement filed on Form S-4 that contains
a preliminary proxy statement (and preliminary prospectus and other relevant materials) filed with the SEC. Investors should read
the registration statement, preliminary proxy statement/prospectus and the other relevant materials when they become available
before making any voting or investment decision with respect to the proposed transaction. These documents can be obtained free of
charge from the sources indicated above.

Non-Solicitation

This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any
sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act of 1933, as amended.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| CARA THERAPEUTICS, INC. |                         |
| By:                     | /s/ RYAN MAYNARD        |
|                         | Ryan Maynard            |
|                         | Chief Financial Officer |

Date: January 17, 2025